HIV-1 env trimer structure {#cesec10}
==========================

Two studies provide new information about the HIV-1 envelope glycoprotein (env) trimer---the molecule that contains the receptor binding sites and membrane fusion machinery that HIV requires to enter its host cells. The first study uses [x-ray crystallography](http://dx.doi.org/10.1126/science.1245625){#interrefs10} to identify the structure of an antigenically near-native, cleaved, stabilised env trimer in complex with a broadly neutralising antibody. The second study uses [cryoelectron microscopy](http://dx.doi.org/10.1126/science.1245627){#interrefs20} to build a structural model of the same trimer in complex with a different antibody. Taken together, these structures should help in the design of env-based vaccines.

Batty about SARS {#cesec20}
================

Researchers have isolated two new [SARS-like coronaviruses](http://dx.doi.org/10.1038/nature12711){#interrefs30} (SL-CoVs) from Chinese horseshoe bats (*Rhinolophus sinicus*) that are more closely related to SARS-CoV coronovirus than previously identified bat coronaviruses, particularly in the receptor-binding domain of the viral spike protein. Notably, the researchers isolated a live SL-CoV from cells infected with bat faecal samples that, like SARS-CoV, uses human angiotensin-converting enzyme II for cell entry. Thus, Chinese horseshoe bats might be natural reservoirs of SARS-CoV and intermediate hosts might not be necessary for human infection by some bat SL-CoVs.
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Resistance to AIDS {#cesec30}
==================

Pathogens and their hosts continually coevolve. Individual hosts try to evade invading pathogens through unique genetic changes in their immune system, and pathogens acquire mutations that allow them to outwit their hosts\' immune responses. To investigate the [effect of coevolution on HIV-1](http://dx.doi.org/10.7554/eLife.01123){#interrefs40}, researchers have used a supercomputer to run more than 3000 genome-wide scans on paired human and viral data from 1071 HIV-positive individuals. They report that human single nucleotide polymorphisms, all of which mapped to the HLA class I region, were associated with 48 HIV-1 aminoacid variants.

Neolithic tuberculosis {#cesec40}
======================

Researchers investigating the skeletal palaeopathological changes of 71 individuals from a late [neolithic](http://dx.doi.org/10.1371/journal.pone.0078252){#interrefs50} site in Hungary report that tuberculosis could have been present in Europe as early as 7000 years ago. They describe a young male with signs of hypertrophic pulmonary osteopathy (HPO)---a disease that is strongly associated with tuberculosis in the archaeological record. The researchers provide evidence that the HPO in this individual was secondary to tuberculosis through detection of *Mycobacterium tuberculosis* complex-specific lipid biomarkers in the skeleton, and by use of ancient DNA analysis.

Atopic dermatitis and *S aureus* {#cesec50}
================================

*Staphylococcus aureus* colonises the skin lesions of most patients with atopic dermatitis, but do these bacteria have a role in the pathogenesis of this inflammatory skin disease? Researchers report that culture supernatants of *S aureus* contain potent mast-cell degranulation activity and identify [*S aureus* δ-toxin](http://dx.doi.org/10.1038/nature12655){#interrefs60} as the factor underlying this activity. *S aureus* isolates from patients with atopic dermatitis produce large amounts of δ-toxin, they report, and colonisation of mice with wild-type *S aureus* but not with mutants deficient in δ-toxin promotes inflammatory skin disease. Therapies that inhibit δ-toxin might therefore help to treat atopic dermatitis.

Vivax malaria in South Korea {#cesec60}
============================

South Korea successfully eliminated vivax malaria in the late 1970s, but, despite continuous malaria control efforts, the disease re-emerged in 1993, initially in soldiers serving in the demilitarised zone between South and North Korea. Analysis of 14 microsatellite DNA loci in 163 isolates of [*Plasmodium vivax* from South Korea](http://dx.doi.org/10.1371/journal.pntd.0002522){#interrefs70} collected between 1994 and 2008 shows that a marked genetic change took place in the parasite population during 2002 and 2003. This finding and other characteristics of the structure of the *P vivax* population suggest that the parasite is being continually introduced into South Korea, probably from North Korea.

Resistance to antimonial drugs {#cesec70}
==============================

Antimonial drugs are effective against visceral leishmaniasis throughout most of the world, but resistance to these drugs has emerged in Bihar, India, which houses 90% of India\'s burden of visceral leishmaniasis. One possible reason for this worrying development is [arsenic contamination](http://dx.doi.org/10.1073/pnas.1311535110){#interrefs80} of drinking water; the Indian subcontinent is the only region where arsenic contamination and resistance to antimonials coexists. To test the hypothesis, researchers serially passaged *Leishmania donovani* in mice exposed to arsenic in their drinking water. After five monthly passages, the parasite became stably resistant to the antimonial drug sodium stibogluconate in vitro and in vivo.
